GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Lilly’s bid to acquire Scorpion was driven by the Scorpion’s PI3Kα inhibitor program that is centered on the drug STX-478. The drug is in clinical studies evaluating its potential in solid tumours and ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals, though skepticism remains.

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

In a significant industry move, Eli Lilly announced plans to acquire Scorpion Therapeutics' experimental cancer therapy, STX-478, for $2.5 billion. This acquisition aims to bolster Eli Lilly's cancer ...

NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.

The company will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials ...

STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. STX-478 could represent the ...

Pharmaceutical giant Eli Lilly & Co. (LLY) is buying privately held Scorpion Therapeutics’ experimental cancer therapy for $2 ...

US pharma major Eli Lilly is to buy the PI3Kα inhibitor program STX-478 from Scorpion Therapeutics, a private US biotech developing small molecule precision oncology therapies.